Status:
COMPLETED
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Lead Sponsor:
Pfizer
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and to...
Eligibility Criteria
Inclusion
- Subjects must have participated and completed the previous Pegvisomant studies or have shown to be unresponsive to other conventional therapies
Exclusion
- ALT/AST\>3 times the ULN or have hepatic disease
- have severe visual field loss, cranial nerve palsies or intracranial HTN that requires surgery to decompress the tumor
- unwilling to self-administer the medication.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00151437
Start Date
November 1 2004
End Date
April 1 2007
Last Update
April 24 2008
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 2B7
2
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 2S2
3
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 2Y9
4
Pfizer Investigational Site
Toronto, Ontario, Canada, M5G 1X5